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In Reply:
We would like to thank de la Gala et al. for their interest in 
this clinical trial.
First, the authors raise a concern about differences 
between the groups in amount of fluids given and the depth 
of anesthesia. It is important for any trial in perioperative 
pulmonary medicine to set rules for volume management, 
hemodynamics, and plateau pressure during ventilation as 
potential confounders in the study protocol. We were well 
To the Editor:
We read with great interest the results of the multicenter ran-
domized controlled trial by Beck-Schimmer et al.1 We congrat-
ulate the authors on performing the first study with sufficient 
statistical power to detect differences in outcomes between two 
anesthetic techniques in lung resection surgery. The authors 
used a recognized anesthetic agent (desflurane) with protective 
(antiinflammatory) lung effects during one-lung ventilation 
(OLV), although they did not measure perioperative biomarkers 
of inflammatory response. Most previous hypotheses proposed 
that this lung-protective role must affect postoperative outcome; 
however, the surprising results of the study by Beck-Schimmer 
et al.1 lead us to think that it is perhaps time to reevaluate these 
hypotheses.
We would like to point out a series of issues that might 
strengthen the conclusions of this study and could be ben-
eficial for future studies. First, we believe that it is impor-
tant to report the amount of fluids administered during 
surgery and the airway pressures during OLV in both 
groups because an association between these variables and 
postoperative lung injury has been demonstrated. Second, 
the authors did not provide data about the depth of anes-
thesia. Did they use the bispectral index to maintain a 
similar grade of hypnosis in both groups? The study sample 
comprised mainly cancer patients, in whom the minimum 
alveolar concentration of inhaled anesthetics is lower than 
in noncancer patients. The percentage of desflurane needed 
to maintain suitable hypnosis could be different. Further-
more, the authors did not show hemodynamic parameters. 
Can the authors ensure that the triple low (recognized vari-
able that could affect outcome) values were similar between 
groups? Third, in parts of the article, the authors base their 
findings on volatile anesthesia. We think that they should 
specify which volatile agent was used. The effects of volatile 
agents differ, and the differences could have an impact on 
outcome. We believe that the authors should have avoided 
the general term volatile anesthesia and stated that their 
results were obtained with desflurane. The bronchodila-
tor effects of volatile anesthetics differ from one drug to 
another and provide the anesthetist with useful informa-
tion, especially in the case of patients with hyperreactivity. 
However, several investigations show that with desflurane, 
bronchodilator effects could disappear when the mini-
mal alveolar concentration is greater than 1, whereas with 
other volatile agents, such as sevoflurane, bronchodilator 
properties are not dose-dependent.2,3 This observation 
could prove to be very important in chronic obstructive 
pulmonary disease and smokers. Second, experimental and 
clinical studies have shown that desflurane has less antioxi-
dant power4–6 than other inhaled agents; the role of oxida-
tive stress in postoperative lung injury during OLV is well 
known. The same research group previously showed better 
postoperative outcome after lung resection surgery when 
they compared sevoflurane with propofol.7
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Lung-protective Role of Halogenated 
Anesthetics
Is It Time to Change This Hypothesis?
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aware of this issue and therefore established a detailed pro-
tocol for the study centers with only very few protocol vio-
lations as reported. In this large trial with 460 patients, we 
trusted the power of randomization to eliminate differences 
in these covariates between the two study arms.1 As a con-
sequence, we are not concerned about the issues raised by 
the authors of the letter. The same argumentation applies to 
the Bispectral Index. The protocol instructed investigators to 
achieve Bispectral Index values of 40 to 60.
Second, the authors are concerned that we subsume the 
effect of desflurane under volatiles in general. As described 
in the letter, differences in clinical effects of the different 
volatile anesthetics do exist and of course we acknowledge 
this. Also, different antioxidant properties of volatile anes-
thetics have been described, which at the same time can 
also be attributed to propofol depending on the formula-
tion and addition of EDTA.2 However, it was not our intent 
to compare different volatile anesthetics. Based on previous 
findings by our group, we do indeed assume that all haloge-
nated anesthetics with trifluorinated carbon (–CF3) groups 
provide protection.3,4 It remains an interesting question if 
our results could be replicated using sevoflurane instead of 
desflurane or a different propofol formulation.
Third, the authors address the issue of anesthetics as being 
lung protective. When discussing protection, it seems key that 
we clearly define the endpoint of such a protection. As already 
shown in several randomized controlled trials, the lung itself 
benefits from a volatile anesthesia, most often through atten-
uation of inflammatory processes, triggered by ventilation 
and/or surgical manipulation.5–7 Based on the result of one 
of these studies, where patients were shown to have less com-
plications after thoracic surgery with volatile anesthetics,6 we 
hypothesized that there would be fewer complications overall 
for patients in the desflurane arm of our trial. Importantly, 
the trial of De Conno et al.6 included only 54 patients with 
surrogate markers as the primary and the clinical outcome 
as the secondary endpoint. With postoperative complications 
using a widely accepted classification system as the primary 
endpoint and an adequately powered approach, our hypoth-
esis was not confirmed with our trial. In conclusion, lung 
protection provided by anesthetics does not lead to an overall 
better postoperative outcome. Our trial also highlights the 
importance of precisely defining study endpoints and proper 
interpretation. Therefore, we do not think this hypothesis 
should be reevaluated as proposed by the authors of the letter. 
In contrast, further trials are needed to test the hypothesis if 
volatile anesthetics improve complications in the entirely dif-
ferent clinical scenarios of major organ injury such as trans-
plantation, which we did not address in this study.
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